A Study of CIN-107 in Patients With Uncontrolled Hypertension

Inclusion Criteria: * Is on a stable regimen of background antihypertensive agent(s) for at least 8 weeks and would be considered a candidate for an additional antihypertensive agent at the time of screening ; * Has a mean seated systolic blood pressure (SBP) ≥ 140 mmHg or ≥ 130 mmHg if diabetic; * Demonstrates ability to be adherent to the study drug and their anti-hypertensive medication during a run-in period * If taking an SGLT2 inhibitor, the regimen must be stable for at least 8 weeks prior to randomization; and * Agrees to comply with the contraception and reproduction restrictions of the study; Exclusion Criteria: * Has a mean seated systolic blood pressure (SBP) ≥180 mmHG; * Has a body mass index (BMI) \>50 kg/m2; * Is using alpha or beta blockers for any primary indication other than systemic hypertension (eg, migraine headache); * Is not willing or not able to discontinue an MRA or potassium sparing diuretic as part of an existing antihypertensive regimen; * Has documented estimated eGFR \<30 mL/min/1.73m2; * Has known and documented New York Heart Association stage III or IV chronic heart failure; * Has had a stroke, transient ischemic attack, hypertensive encephalopathy, acute coronary syndrome, or hospitalization for heart failure within 6 months before screening; * Major cardiac surgery within 6 months before Screening; * Has chronic permanent atrial fibrillation; * Has uncontrolled diabetes with glycated hemoglobin \>10% at Screening; * Has planned dialysis or kidney transplantation planned during the course of the study; * Prior solid organ transplant and/or cell transplants; * Sodium \<130 mEq/L; * Potassium \<3.5 mEq/L; * Potassium \>5 mEq/L; * White blood cell count \>15 × E9/L or absolute neutrophil count \<1 × E9/L at Screening; * Is positive for HIV antibody, hepatitis C virus RNA, or hepatitis B surface antigen; * Has typical consumption of ≥14 alcoholic drinks weekly;